In this study all analysis was performed on tumour samples taken before tamoxifen treatment, and although we do not find that active c-Src correlates with de novo endocrine resistance, it is interesting that within our cohort the survival benefit was only in ER+/PgR+ patients and not in the ER+/PgR negative group. The gene discussed is SRC; the disease is neoplasm.